Why MannKind Corporation’s (MNKD) Stock Is Up 5.53%
As of Wednesday, August 19, MannKind Corporation’s MNKD share price has surged by 5.53%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company’s pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Commentary & Analysis
Why MannKind Corporation’s (MNKD) Stock Is Down 8.30%
As of Thursday, August 06, MannKind Corporation’s MNKD share price has dipped by 8.30%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why MannKind Corporation’s (MNKD) Stock Is Up 6.65%
As of Friday, July 24, MannKind Corporation’s MNKD share price has surged by 6.65%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why MannKind Corporation’s (MNKD) Stock Is Up 7.78%
As of Thursday, July 02, MannKind Corporation’s MNKD share price has surged by 7.78%, which has investors questioning if this is right time to sell.Michael Rose
Why MannKind Corporation’s (MNKD) Stock Is Up 5.73%
As of Friday, June 26, MannKind Corporation’s MNKD share price has surged by 5.73%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | MNKD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,334.4 | $292.6 | 48% |
|
| Shares Out (Mil) | 309.2 | 54.4 | 83% |
|
| Institutional Ownership | 96.5% | 93.2% | 70% |
|
| Float (Mil) | 297.5 | 40.2 | 80% |
|
| Beta | 1.10 | 0.94 | 66% |
|
| Avg Daily Volume (000s) | 3,978 | 544 | 90% |
|
| Price Change (52-week) |
4.5% | 59.7% | 48% |
|
| Growth | MNKD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 39.9% | 13.6% | 93% |
|
| Net Income (5yr) | 16.0% | (10.1%) | 66% |
|
| EPS (5yr) | 15.8% | 16.0% | 59 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (10.1%) | (15.6%) | 58% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.005) | $0.030 | $0.128 | |
| Month Ago EPS | $0.020 | $0.085 | $0.193 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 2 | 1 | 1 | |
| Three Months Ago EPS | $0.020 | $0.085 | $0.193 | |
| Year/Year Chg | (91.9%) | 50.0% | 465.0% | |
| Financials | MNKD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $394 | $37 | 38% |
|
| Net Income (TTM) (Mil) | ($44) | ($43) | 17% |
|
| EPS (TTM) | ($0.158) | ($1.400) | 34% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | ($31) | 21% |
|
| Net Cash Flow (TTM) (Mil) | ($4) | $2 | 35% |
|
| Long-Term Debt (Q1) (Mil) | $421 | $4 | 57% |
|
| Enterprise Value (Q1) (Mil) | $1,574 | $164 | 46% |
|
| Valuation | MNKD | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.83 | na |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | MNKD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 75.4% | 64.2% | 85% |
|
| Net Margin | (11.1%) | (75.9%) | 20% |
|
| ROA | (7.6%) | (47.5%) | 27% |
|
| ROE | 71.4% | (55.0%) | 95% |
|
| Liabilities to Assets | 109.2% | 29.6% | 95% |
|
| F-Score | 2 | 3 | 7% |
|
MannKind Corporation did not pass any screens on 8/21/2026.
